The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | Novel agents in CLL: the current landscape
The development of novel agents for treating chronic lymphocytic leukemia (CLL) has transformed the field in recent years. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden, William Wierda, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, speaks about the most promising novel agents on the scene. He includes: PI3K inhibitors; checkpoint inhibitors and their use for combatting Richter’s transformation; reversible BTK inhibitors; and cellular strategies like CAR T-cells. He also discusses an upcoming clinical trial, which will combine checkpoint inhibitors, CTLA-4 antibodies, and PD-1 antibodies for CLL therapy.
